PH plays key role to fight dengue fever

business.inquirer.net /215327/ph-plays-key-role-to-fight-dengue-fever

It seems the Philippines and the fight against dengue fever are inextricably intertwined. It was here, in 1954,
where the first epidemic of severe dengue was reported and laboratory-confirmed. More than half a century later,
in April this year, it was the Philippines that initiated the worlds first public dengue immunization drive, sending a
strong message that this element is a critical addition to integrated disease prevention efforts needed to more
effectively manage dengue burden.

The government-funded, public-school-based program benefited 489,003 Grade 4 pupils in the National Capital
Region, Central Luzon (Region 3) and Calabarzon (Region 4A). Within four months, the program achieved 67
percent coverage.

The Philippines is somehow taking ownership of the disease. After all, dengue fever was initially known as
Philippine hemorrhagic fever, said Prof. Tikki Pang of the National University of Singapores Lee Kuan Yew
School of Public Policy.

ADVERTISEMENT

He related that the Philippines also played a significant role in the development of Dengvaxia, the first-ever
vaccine for dengue fever that is now being incorporated into a countrys multipronged attack on the disease to
ward off its outbreak.

Participated

He said: The Philippines participated in all three phases of the vaccines clinical development and of the 40,000
volunteers from around the world, 3,500 children were from the Philippines, setting up clinical trial sites in
Alabang, Muntinlupa City (Phase 1); Barangay Del Remedios in San Pablo City (Phase 2); and Barangay
Guadalupe in Cebu City along with Barangay Del Remedios (Phase 3). So researchers and volunteers here
already knew its safety profile and effectiveness even before it was cleared for worldwide release.

According to Dr. Su-Peing Ng, global medical head of Sanofi Pasteur, the vaccine has been shown to reduce the
occurrence of symptomatic dengue by 65.6 percent; prevent severe dengue cases by 93.2 percent; and prevent
hospitalization by 80.8 percent.

Ng said: Dengue represents significant burden in endemic countries like the Philippines. The Philippines spends
P16.7 billion a year dealing with this disease. For one hospitalized patient that would be about P27,000 worth of
bills not including the lost days in school or work.

She said vaccination can help the public health community in dengue-endemic nations tip the balance in favor of
dengue control, adding that vaccination adds a critical line of defense to comprehensive dengue prevention
efforts.

Correctly implement

While the newly licensed vaccine against the dengue virus may not be a silver bullet for dengue and its
effectiveness depends on the local epidemiology of dengue as well as how intense the transmission is,
Dengvaxia could still lead to a decrease in the number of cases of the disease if implemented correctly.

ADVERTISEMENT

This is why the World Health Organizations position for the use of Dengvaxia, is for countries to consider
introduction of the vaccine only in communities that have the highest transmission rates and focusing on them,
said Pang.

He added that based on the same WHO position, dengue vaccination should be a part of a comprehensive
1/2
dengue control strategy, which includes well-executed and sustained vector control, evidence-based best
practices for clinical care and strong dengue surveillance.

Despite recording more than 200,000 dengue fever cases in 2015, the Philippines, citing a Department of Health
data, already listed 70,697 suspected dengue cases as of July, a 19-percent increase compared to the same
period in 2015 (59,342).

2/2